Trailing-twelve-month (TTM) revenue is $458.09 Million with a year-over-year growth of +34.41%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $100,055,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $108,386,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $117,700,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $131,948,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $458,089,000 |
Current P/S: $3,300,124,618 market capitalization ÷ $458,089,000 TTM revenue = 7.20x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $131.95M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:40:55.429Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20162016-12-31 · USD | FY20172017-12-31 · USD | FY20182018-12-31 · USD | FY20202020-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Care Dx | $30M | N/A | N/A | N/A | N/A | N/A |
| Digital And Other | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $8M | $7M | $10M | $9M | $11M | N/A |
| Non-US | N/A | N/A | N/A |
$458.09M
$458.09 Million
+34.41%
vs. $340.81M a year ago (TTM)
+12.56%
5 Year compound annual growth rate
1 Year
+34.41%
3 Year
+13.98%
5 Year
+12.56%
10 Year
+30.88%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $379.81M | +$46.02M | +13.79% |
| 2024 | $333.79M | +$53.46M | +19.07% |
| 2023 | $280.32M | ($41.47M) | (12.89%) |
| 2022 | $321.79M | +$25.40M | +8.57% |
| 2021 | $296.40M | +$104.20M | +54.22% |
| 2020 |
TTM Growth
+34.41%
3-Year CAGR
+13.98%
5-Year CAGR
+12.56%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:40:55.429Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| $9M |
| N/A |
| N/A |
| Olerup | $11M | N/A | N/A | N/A | N/A | N/A |
|---|
| Post Transplant | N/A | $34M | N/A | N/A | N/A | N/A |
|---|
| Pre Transplant | N/A | $15M | N/A | N/A | N/A | N/A |
|---|
| Product | N/A | N/A | N/A | N/A | $41M | $48M |
|---|
| Royalty | N/A | N/A | $300,000 | N/A | N/A | N/A |
|---|
| Service | N/A | N/A | N/A | N/A | $249M | $274M |
|---|
| N/A |
| $20M |
| Rest Of The World | $494,000 | $389,000 | $873,000 | $789,000 | $5M | N/A |
|---|
| UNITED STATES | $104M | $163M | $258M | $263M | $318M | $360M |
|---|
| $192.19M |
| +$65.13M |
| +51.25% |
| 2019 | $127.07M | +$50.50M | +65.95% |
| 2018 | $76.57M | +$28.25M | +58.45% |
| 2017 | $48.32M | +$7.69M | +18.93% |
| 2016 | $40.63M | +$12.49M | +44.37% |
